US Breast Cancer Drug Market 2019-2025 Opportunity: $ 20 Billion
DUBLIN–(BUSINESS WIRE)–The “US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025” drug pipelines has been added to…
Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025” drug pipelines has been added to…
Acquisition Includes Novel Late-Stage Renal Cell Carcinoma Candidate, PT2977 KENILWORTH, N.J. & DALLAS–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;–Merck (NYSE:…
Shipments for Follow-on Order Under Existing Supply Agreement Will Commence This Quarter STONY BROOK, N.Y.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24apdn&src=ctag" target="_blank"gt;$apdnlt;/agt; lt;a href="https://twitter.com/hashtag/PCR?src=hash"…
Data Supports Continued Dose Escalation and Further Investigation in Metastatic Renal Cell Carcinoma (mRCC) MAINZ, Germany–(BUSINESS WIRE)–EXUMA Biotechnology and affiliate…
Completion of Gene-to-Lead phase for first discovery project targeting METTL3/METTL14 complex NEW YORK & LEIDEN, Netherlands–(BUSINESS WIRE)–Gotham Therapeutics, a biotechnology…
ZURICH–(BUSINESS WIRE)–Regulatory News: Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has…
SAN FRANCISCO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/EHA24?src=hash" target="_blank"gt;#EHA24lt;/agt;–Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that…
– Vofatamab activates immune changes in immunologically cold tumors and in combination increases patient response rates – – Data from…
PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing Process
The KEYTRUDA breast cancer clinical development program encompassesseveral internal and external collaborative studies, including threeongoing registration-enabling studies in TNBC.